Comparative Pharmacology
Head-to-head clinical analysis: NOXIVENT versus PROAIR HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOXIVENT versus PROAIR HFA.
NOXIVENT vs PROAIR HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Noxivent is a synthetic analog of epinephrine that acts as a non-selective alpha and beta adrenergic receptor agonist. It binds to alpha-1 receptors causing vasoconstriction, alpha-2 receptors reducing insulin secretion, beta-1 receptors increasing heart rate and contractility, and beta-2 receptors causing bronchodilation and vasodilation. Its primary effect in septic shock is increasing mean arterial pressure via vasoconstriction.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
700 mg orally twice daily with food.
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
None Documented
None Documented
Terminal elimination half-life 4-6 hours; prolonged in renal impairment (up to 12 hours) requiring dose adjustment.
Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief.
Primarily renal (70-80% unchanged), with 10-15% biliary/fecal. Minor metabolism via ester hydrolysis.
Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal.
Category C
Category C
Beta-2 Agonist Bronchodilator
Beta-2 Agonist Bronchodilator